Can Amarin Win Its Vascepa Appeal Case? Analyst Weighs In

It is gearing up to be a big week for Amarin (AMRN), as it awaits the opening of the appeal case for its high triglyceride treatment, Vascepa.To recap, in March, Amarin lost a patent court case against generic drug makers, Hikma Pharmaceuticals and Dr. Reddy’s, which sought to sell their own versions of Vascepa. Amarin immediately filed an appeal, and an oral hearing will commence on Wednesday, September 2.Ahead of the court date, Stifel analyst Derek Archila consulted with two IP specialists on the matter, and both have indicated Amarin has a 55% chance of succeeding in its appeal. However, …read more

Source:: Yahoo Finance

      

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.